On Oct 18, major Wall Street analysts update their ratings for $Intuitive Surgical (ISRG.US)$, with price targets ranging from $525 to $555.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $416 to $549.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $475 to $525.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $518 to $535.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $525 to $555.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
The expectation of a significant revenue outperformance for FY25 appears to be a prevailing sentiment. This perspective is reinforced by the company's recent quarterly report, which prompted a revision of the estimated earnings per share for FY25, increasing it approximately by 3%.
Intuitive Surgical registered 'strong' results for Q3, particularly excelling in the two most vital metrics—DV5 placements and procedure growth. Seven months post the U.S. approval of da Vinci 5, Intuitive Surgical is experiencing significant post-launch growth momentum. The early adoption of DV5 is surpassing the initial uptake of the fourth-generation system, indicating a promising potential for accelerated growth as we look towards 2025.
The company's Q3 earnings and revenue exceeded expectations, accompanied by a procedure volume growth of 18% which also surpassed the consensus by 100bps. With a series of regulatory approvals for Dv5, it is anticipated that the growth momentum of Dv5 will be maintained, even as it enters into a wider release in the second half of FY25.
The conviction in the sustained upward potential of Intuitive Surgical strengthens, supporting its premium valuation. It stands out as a top-tier long-term growth prospect following the company's performance that surpassed estimates and showcased accelerated growth across various metrics.
Here are the latest investment ratings and price targets for $Intuitive Surgical (ISRG.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
